Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 2/20 | 0.66 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.37 |
| ▸ | SPNS2 | Q8IVW8 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3463108 | 0.95 | CENPE (0.65) | CENPES1PR1S1PR5S1PR3XDH | |
| SCHEMBL3461735 | 0.93 | CENPE (0.63) | CENPES1PR1S1PR5S1PR3SPNS2 | |
| SCHEMBL4794305 | 0.92 | CENPE (0.67) | CENPES1PR1S1PR5S1PR3SPNS2 | |
| SCHEMBL3461702 | 0.88 | CENPE (0.69) | CENPES1PR1S1PR5S1PR3XDH | |
| SCHEMBL13161463 | 0.88 | CENPE (0.69) | CENPES1PR1S1PR5S1PR3XDH | |
| SCHEMBL4441782 | 0.87 | CENPE (0.68) | CENPES1PR1S1PR5S1PR3XDH | |
| SCHEMBL13161504 | 0.87 | CENPE (0.68) | CENPES1PR1S1PR5S1PR3XDH | |
| SCHEMBL3463009 | 0.86 | CENPE (0.67) | CENPES1PR1S1PR5S1PR3XDH | |
| SCHEMBL13161524 | 0.86 | CENPE (0.66) | CENPES1PR1S1PR5S1PR3XDH | |
| SCHEMBL3462351 | 0.86 | CENPE (0.66) | CENPES1PR1S1PR5S1PR3XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1742907-A4 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| EP-1742907-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005107762-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885S1PR1 2943/4885S1PR5 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.